BJDX
Bluejay Diagnostics, Inc.NASDAQHealthcare$1.95+5.64%ClosedMarket Cap: $884,405
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.15
P/S
0.00
EV/EBITDA
0.61
DCF Value
$10.79
FCF Yield
-666.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-145.5%
ROA
-96.2%
ROIC
-113.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-1.5M | $-1.4M | $-2.37 | — |
| FY 2025 | $0.00 | NaN% | $-7.0M | $-6.8M | $-15.25 | — |
| Q3 2025 | $0.00 | NaN% | $-1.6M | $-1.6M | $-4.04 | — |
| Q2 2025 | $0.00 | NaN% | $-2.0M | $-2.0M | $-5.64 | — |
| Q1 2025 | $0.00 | NaN% | $-1.9M | $-1.9M | $-46.56 | — |
| Q4 2024 | $0.00 | NaN% | $-1.5M | $-1.4M | $-404.04 | — |
| FY 2024 | $0.00 | NaN% | $-7.2M | $-7.7M | $-456.76 | — |
| Q3 2024 | $0.00 | NaN% | $-1.4M | $-1.5M | $-37.00 | — |
| Q2 2024 | $0.00 | NaN% | $-1.9M | $-2.5M | $-66.60 | — |
| Q1 2024 | $0.00 | NaN% | $-2.4M | $-2.3M | $-62.64 | — |
| Q4 2023 | $0.00 | NaN% | $-2.4M | $-2.3M | $-59.48 | — |
| FY 2023 | $0.00 | NaN% | $-10.3M | $-10.0M | $-290.48 | — |